"Remember the Ford Pinto? It was a small car with a poorly located fuel tank, which happened to explode if someone went into the back of it. Ford had lobbied US regulators against making changes to the car, producing a cost/benefit analysis that said 'only' 180 people were likely to be killed by the Pinto's faults. And that was not worth the $137m . . . that would have been needed to sort out the problem. The regulators were not impressed. Nor were the courts. Nor were the public. Ford's reputation went through the floor.
"Is the same thing happening in pharmaceuticals? " [The Independant]
